Darolutamide and Lopinavir and Ritonavir Solution
Determining the interaction of Darolutamide and Lopinavir and Ritonavir Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone. MANAGEMENT: Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling. References "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Professional:MONITOR: Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone.
MANAGEMENT: Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Generic Name: lopinavir / ritonavir
Brand name: Kaletra
Synonyms: Lopinavir and ritonavir, Lopinavir and Ritonavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Darolutamide-Lopinavir and Ritonavir Tablets
- Darolutamide-Lopreeza
- Darolutamide-Lopressor
- Darolutamide-Lopressor (Metoprolol Injection)
- Darolutamide-Lopressor (Metoprolol Tablets)
- Darolutamide-Lopressor HCT
- Lopinavir and Ritonavir Solution-Darpaz
- Lopinavir and Ritonavir Solution-Darunavir
- Lopinavir and Ritonavir Solution-Darunavir and Cobicistat
- Lopinavir and Ritonavir Solution-Darunavir Oral Suspension
- Lopinavir and Ritonavir Solution-Darunavir Tablets
- Lopinavir and Ritonavir Solution-Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide